Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HXHNB
ADC Name
Trastuzumab-C-22
Synonyms
Trastuzumab-C-22
   Click to Show/Hide
Organization
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Drug Status
Investigative
Drug-to-Antibody Ratio
3.38
Structure
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
WO2023221971A1 NEC49-4 Payload
  Payload Info 
Linker Name
KR1020250002133A Trastuzumab-C-22 Linker
  Linker Info 
Conjugate Type
site-specific conjugation
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
0.053
nM
CVCL_1259
Breast ductal carcinoma
Half Maximal inhibitory Concentration (lC50) 
0.103
nM
CVCL_1603
Gastric tubular adenocarcinoma
Half Maximal Effective Concentration (EC50) 
14.05
nM
CVCL_1259
Breast ductal carcinoma
Emax (TNF-a) 
1562.5
pg/mL
CVCL_1259
Breast ductal carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.053 nM High HER2 expression (HER19 +++)
Method Description
Trastuzumab-C-21 was tested in HCC1954,80ul,18&#4524h
In Vitro Model Breast ductal carcinoma HCC1954 cells CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.103 nM High HER2 expression (HER19 +++)
Method Description
Trastuzumab-C-21 was tested in NCI-N87,80ul,18&#4524h
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 14.05 nM High HER2 expression (HER19 +++)
Method Description
Trastuzumab-C-21 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model Breast ductal carcinoma HCC1954 cells CVCL_1259
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Emax (TNF-a) 1562.5 pg/mL High HER2 expression (HER19 +++)
Method Description
Trastuzumab-C-21 was tested in HCC1954 and PBMC,50ul,24h
In Vitro Model Breast ductal carcinoma HCC1954 cells CVCL_1259
References
Ref 1 Anticipate-drug zygotes, pharmacological compositions and Uses